相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Safety and immunogenicity of the measles vector-based SARS-CoV-2 vaccine candidate, V591, in adults: results from a phase 1/2 randomised, double-blind, placebo-controlled, dose-ranging trial
Frederic Vanhoutte et al.
EBIOMEDICINE (2022)
Safety and immunogenicity of a measles-vectored SARS-CoV-2 vaccine candidate, V591/TMV-083, in healthy adults: results of a randomized, placebo-controlled Phase I study
Odile Launay et al.
EBIOMEDICINE (2022)
Systemic viral spreading and defective host responses are associated with fatal Lassa fever in macaques
Nicolas Baillet et al.
COMMUNICATIONS BIOLOGY (2021)
Effects of N-Linked Glycan on Lassa Virus Envelope Glycoprotein Cleavage, Infectivity, and Immune Response
Xueqin Zhu et al.
VIROLOGICA SINICA (2021)
Pathogenicity and virulence mechanisms of Lassa virus and its animal modeling, diagnostic, prophylactic, and therapeutic developments
Hannah L. Murphy et al.
VIRULENCE (2021)
A single-shot Lassa vaccine induces long-term immunity and protects cynomolgus monkeys against heterologous strains
Mathieu Mateo et al.
SCIENCE TRANSLATIONAL MEDICINE (2021)
Clinical characterization of Lassa fever: A systematic review of clinical reports and research to inform clinical trial design
Laura Merson et al.
PLOS NEGLECTED TROPICAL DISEASES (2021)
Inter-Lineage Variation of Lassa Virus Glycoprotein Epitopes: A Challenge to Lassa Virus Vaccine Development
Francis Ifedayo Ibukun
VIRUSES-BASEL (2020)
Lassa fever in Benin: description of the 2014 and 2016 epidemics and genetic characterization of a new Lassa virus
Anges Yadouleton et al.
EMERGING MICROBES & INFECTIONS (2020)
Antibody therapy for Lassa fever
Robert W. Cross et al.
CURRENT OPINION IN VIROLOGY (2019)
Vaccines inducing immunity to Lassa virus glycoprotein and nucleoprotein protect macaques after a single shot
Mathieu Mateo et al.
SCIENCE TRANSLATIONAL MEDICINE (2019)
A Vaccine Platform against Arenaviruses Based on a Recombinant Hyperattenuated Mopeia Virus Expressing Heterologous Glycoproteins
Xavier Carnec et al.
JOURNAL OF VIROLOGY (2018)
Lassa virus glycoprotein: stopping a moving target
Kathryn M. Hastie et al.
CURRENT OPINION IN VIROLOGY (2018)
Immunogenicity, safety, and tolerability of the measles-vectored chikungunya virus vaccine MV-CHIK: a double-blind, randomised, placebo-controlled and active-controlled phase 2 trial
Emil C. Reisinger et al.
LANCET (2018)
Non-neutralizing antibodies elicited by recombinant Lassa-Rabies vaccine are critical for protection against Lassa fever
Tiago Abreu-Mota et al.
NATURE COMMUNICATIONS (2018)
Human-monoclonal-antibody therapy protects nonhuman primates against advanced Lassa fever
Chad E. Mire et al.
NATURE MEDICINE (2017)
Epitope specificity plays a critical role in regulating antibody-dependent cell-mediated cytotoxicity against influenza A virus
Wenqian He et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2016)
Immunogenicity, safety, and tolerability of a recombinant measles-virus-based chikungunya vaccine: a randomised, double-blind, placebo-controlled, active-comparator, first-in-man trial
Katrin Ramsauer et al.
LANCET INFECTIOUS DISEASES (2015)
Arenavirus Glycan Shield Promotes Neutralizing Antibody Evasion and Protracted Infection
Rami Sommerstein et al.
PLOS PATHOGENS (2015)
Toxicology, biodistribution and shedding profile of a recombinant measles vaccine vector expressing HIV-1 antigens, in cynomolgus macaques
Clarisse Lorin et al.
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY (2012)
Immune Responses and Lassa Virus Infection
Marion Russier et al.
VIRUSES-BASEL (2012)
Risk Maps of Lassa Fever in West Africa
Elisabeth Fichet-Calvet et al.
PLOS NEGLECTED TROPICAL DISEASES (2009)
A ML29 reassortant virus protects guinea pigs against a distantly related Nigerian strain of Lassa virus and can provide sterilizing immunity
Ricardo Carrion et al.
VACCINE (2007)
分享论文
